First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743
dc.contributor.author | Peters, S. | |
dc.contributor.author | Scherpereel, A. | |
dc.contributor.author | Cornelissen, R. | |
dc.contributor.author | Oulkhouir, Y. | |
dc.contributor.author | Greillier, L. | |
dc.contributor.author | Kaplan, M. A. | |
dc.contributor.author | Talbot, T. | |
dc.date.accessioned | 2024-04-24T16:10:49Z | |
dc.date.available | 2024-04-24T16:10:49Z | |
dc.date.issued | 2021 | |
dc.department | Dicle Üniversitesi | en_US |
dc.description | Congress of the European-Society-for-Medical-Oncology (ESMO) -- SEP 16-21, 2021 -- ELECTR NETWORK | en_US |
dc.description.abstract | [Abstract Not Available] | en_US |
dc.description.sponsorship | European Soc Med Oncol,Japanese Soc Med Oncol | en_US |
dc.description.sponsorship | Bristol Myers Squibb | en_US |
dc.description.sponsorship | Bristol Myers Squibb. | en_US |
dc.identifier.doi | 10.1016/j.annonc.2021.08.2146 | |
dc.identifier.endpage | S1342 | en_US |
dc.identifier.issn | 0923-7534 | |
dc.identifier.issn | 1569-8041 | |
dc.identifier.startpage | S1341 | en_US |
dc.identifier.uri | https://doi.org/10.1016/j.annonc.2021.08.2146 | |
dc.identifier.uri | https://hdl.handle.net/11468/15130 | |
dc.identifier.volume | 32 | en_US |
dc.identifier.wos | WOS:000700527704025 | |
dc.identifier.wosquality | Q1 | |
dc.indekslendigikaynak | Web of Science | |
dc.language.iso | en | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.ispartof | Annals of Oncology | |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | [No Keyword] | en_US |
dc.title | First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743 | en_US |
dc.title | First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743 | |
dc.type | Conference Object | en_US |